1.. Introduction {#s1}
================

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an arrhythmogenic cardiac disorder associated with a characteristic PVT induced by physical activity, stress, or catecholamine infusion, which can deteriorate into ventricular fibrillation (VF). Patients typically present with recurrent syncope, seizures, or sudden death after physical activity or emotional stress.^[@CVQ229C1]^

Two major genes have been implicated in CPVT. One is transmitted as an autosomal dominant trait caused by mutations in the *RyR2* gene.^[@CVQ229C2]^ More than 70 distinct *RyR2* mutations have been reported.^[@CVQ229C2]--[@CVQ229C5]^ The other is a recessive form caused by mutations in the cardiac-specific isoform of CASQ2.^[@CVQ229C6],[@CVQ229C7]^ Mutant *RyR2*^[@CVQ229C2]^ and *CASQ2*^[@CVQ229C6]^ may influence myocyte Ca^2+^ homeostasis resulting in inappropriate 'leakiness' of RyR2-Ca^2+^ release channels, causing increases in their basal activity, alterations in their phosphorylation status or defective interactions of RyR2 with other molecules or ions, including FKBP12.6^[@CVQ229C8]^, CASQ2, or Mg^2+^, or its abnormal activation by extra- or intraluminal Ca^2+^.^[@CVQ229C9]^ Such changes recently have been investigated using murine CPVT models containing either *R4497C*^[@CVQ229C10]^ or *P2328S* modifications in the *RyR2* gene.^[@CVQ229C11]^

There are also reports associating clinical atrial as opposed to ventricular arrhythmias with *RyR2* mutations. A large in-frame deletion in the N-terminal region of *RyR2* has recently been correlated with progressive atrial ventricular block, sino-atrial node dysfunction, atrial fibrillation (AF), and atrial standstill in addition to the typical CPVT.^[@CVQ229C12]^ Supraventricular arrhythmias including isolated atrial ectopic beats, non-sustained supraventricular tachycardia, and short runs of AF have been reported during exercise with an onset pattern similar to that of the ventricular arrhythmias.^[@CVQ229C1],[@CVQ229C13],[@CVQ229C14]^ So have episodes of sinus bradycardia.^[@CVQ229C1],[@CVQ229C14],[@CVQ229C15]^

However, apart from a recent, important report on the *RyR2-R176Q* heterozygotic system, there have been few studies of atrial arrhythmogenesis in genetically modified *RyR2* mouse models.^[@CVQ229C16]^ In addition, all these studies were confined to heterozygotic, omitting homozygotic variants resulting from the genetic modifications. The present study accordingly explores for such arrhythmogenic properties and their possible physiological background in a recently developed *RyR2-P2328S* murine model for CPVT^[@CVQ229C11]^ for the first time, studying both heterozygotic and homozygotic systems. They thus extend previous findings on ventricular arrhythmogenic properties in the *P2328S* system. We evaluated the presence or absence of anatomical abnormalities, spontaneous and atrial arrhythmogenicity, and alterations in action potential recovery in intact anaesthetized animals, isolated perfused hearts, and altered Ca^2+^ homeostasis in atrial myocytes.

2.. Methods {#s2}
===========

2.1. Animals {#s2a}
------------

Heterozygote *RyR2^+/S^*, homozygote *RyR2^S/S^*, and wild-type (WT) mice (aged 3--6 months) with an inbred 129/Sv genetic background (Harlan, UK) were generated as described on a previous occasion.^[@CVQ229C11]^ They were kept in plastic cages at room temperature in an animal facility, given free access to sterile rodent chow and water and subjected to 12h light/dark cycles. All procedures were performed in institutional premises approved under the UK Animals (Scientific Procedures) Act (1986), under UK Home Office project licence no. PPL No. 80/1974, approved by a university ethics review board, accordingly also in conformity with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).

2.2. *In vivo* surface electrocardiographic recordings {#s2b}
------------------------------------------------------

Mice were anaesthetized using avertin (2,2,2-tribromo-ethanol: Sigma, Poole, Dorset, UK) in a 24 mg/mL solution at 0.10 mL/(10 g body weight) dosage injected into the left peritoneal cavity 5 min before electrical recording. They were placed on a heating pad with body temperature monitoring for three-lead electrocardiographic (ECG) measurements using subcutaneous needle electrodes employing a Powerlab 26T system (AD Instruments, Hastings, UK). The digital recordings (16 bit, 2 kHz/channel) were analysed using the Chart v6.0 program (AD Instruments, Oxfordshire, UK) giving signal-averaged ECGs and ECG parameters in which corrected, QT was given as QTc = QT/(RR/100)^1/2^.^[@CVQ229C17]^ This choice of injected rather than inhalational anaesthesia permitted experiments using oesophageal-stimulating electrodes. Preliminary experiments on WT animals also explored ketamine--xylazine anaesthetic (1.8 mL ketamine hydrochloride at 100 mg/mL, 0.35 mL xylazine hydrochloride at 23.32 mg/mL, and 2.85 mL of sterile phosphate base solution; administration at 0.10 mL/(10 g body weight). However, this gave greater bradycardic effects (heart rates 260.6 ± 18.6, *n* = 12 vs. 410.4 ± 14.5 b.p.m., *n* = 19; *P* \< 0.01) in agreement with previous reports.^[@CVQ229C18]^ An isoproterenol stress protocol involved recording the baseline ECG in lead II for 10 min, followed by intraperitoneal injection of 2.0 mg/kg isoproterenol.

2.3. *In vivo* stimulation studies {#s2c}
----------------------------------

A further series of *in vivo* experiments then applied programmed stimulation procedures both before and after the application of isoproterenol during the ECG recordings in the anaesthetized mice. This used an ultraminiature octapolar 1.1F electrophysiological oesophageal catheter that permitted connections to stimulating leads (EPR-800, Millar Instrument, Inc., Houston, TX, USA). The stimulation protocols were performed after 5 min of stable simultaneous recordings of the baseline surface ECG. The stimulation protocols first applied oesophageal pacing at a 100 ms cycle length (CL) for 30 s. Secondly, a burst pacing procedure involved pacing hearts at a 40 ms CL of 40 ms in bursts of 2 s duration. This CL was then decreased in successive 2 s bursts in 2ms decrements following sets of three cycles until a CL of 20 ms was reached.

2.4. Electrophysiological studies in Langendorff-perfused hearts {#s2d}
----------------------------------------------------------------

Langendorff-perfused hearts showing clear-cut 1:1 atrioventricular conduction during intrinsic activity following cannulation were studied as described previously^[@CVQ229C19],[@CVQ229C20]^ using Krebs--Henseleit (K--H) solution (in mM: NaCl 119, NaHCO~3~ 25, KCl 4.0, KH~2~PO~4~ 1.2, MgCl~2~ 1.0, CaCl~2~ 1.8, glucose 10, and sodium pyruvate 2.0) maintained at pH 7.4 by bubbling with 95% O~2~--5% CO~2~ (British Oxygen, Manchester, UK) using the following recording methods: (i) bipolar electrogram (BEG) electrodes with 1mm interpole spacings were placed on the left atrium and left ventricle. Hearts were initially paced for \>5 min at 10 Hz to permit them to regain a steady state. The resulting electrogram signals were amplified for band-pass filtering between 30 Hz and 1 kHz. (ii) Left atrial monophasic action potentials (MAPs) were recorded with a microMAP electrode (Linton Instruments, Harvard Apparatus, UK) for band-pass filtering between 0.5 Hz and 1 kHz. All signals were recorded using an NL100AK head stage and NL104 amplifier unit, then band-pass filtered (Neurolog NL 125/6 Filter, Neurolog, Hertfordshire, UK), then digitized at 5 kHz by a micro 1401plus MKII laboratory interface (Cambridge Electronic Design, Cambridge, UK) using Spike2 software (Cambridge Electronic Design), and action potential durations corresponding to the time at 90% recovery of the MAPs to baseline (APD~90~) were determined.

Three types of pacing protocols were used. (i) Hearts were studied at their intrinsic rates in the absence of stimulation. (ii) Regular pacing at 10 Hz used 2ms square-wave stimuli set at twice the excitation threshold (Grass S48 stimulator; Grass-Telefactor, Slough, UK). (iii) Programmed electrical stimulation (PES) began using standard baseline pacing stimuli at frequencies of 10 Hz for 20 s. Drive trains of eight paced beats (S1) were each followed by an extra-stimulus (S2) every ninth beat, initially at an S1S2 interval equal to the pacing interval. Each subsequent cycle reduced the S1S2 interval by 1 ms until atrial refractoriness was reached.

2.5. Atrial myocyte isolation {#s2e}
-----------------------------

Atrial myocyte isolation used methods described previously.^[@CVQ229C20]^ Briefly, hearts were rapidly excised and cannulated in ice-cold K--H solution before Langendorff perfusion with a succession of buffers (in mmol/L): NaCl 125; KCl 4.75; MgSO~4~ 1.2; KH~2~PO~4~ 1.2; HEPES 30; glucose 10; taurine 50, titrated to pH 7.4 with NaOH to which was added 750 μM Ca^2+^, 5 mM nitrilotriacetic acid, 1 mg/ml collagenase type II (Worthington, NJ, USA), and 1 mg/mL hyaluronidase, respectively, at a stable temperature of 37 °C. The heart was then removed and the atrial appendages excised and chopped into pieces in buffer with reduced enzyme. These were incubated for 5--10 min with gentle manual agitation. Cells were then separated from the enzymatic solution by centrifuging at 243*g* for 3 min. The isolated cells were washed using BSA-containing wash buffer, followed after 5 min by centrifugation at 30*g* for 2 min. The cells were resuspended in normal K--H solution and, after 5 min, centrifuged again at 30*g* for 2 min. The cells were maintained at room temperature for the experiments that followed and used within 4--6h.

2.6. Measurements of Ca^2+^ transients {#s2f}
--------------------------------------

Cells placed on a Grade 1 circular laminin-coated cover slip (Menzel, Glasbearbeitungswerk, Germany) forming the floor of a 1.5 mL perfusion chamber were incubated with 5 µM Fluo-3 AM (Molecular Probes, Leiden, The Netherlands) in K--H buffer (1.2 mM CaCl~2~) for 10--20 min in the dark before washout. Cells were scanned using a Leica TCS SP5 confocal scanning laser microscopy system incorporating a Leica 6000 CS inverted microscope with a ×63 water-immersion objective lens (numerical aperture 1.2; confocal aperture 600 μm; slice thickness 20.5 μm). The Fluo-3 was excited using a 488 nm argon laser, and emission collected between 505 and 550 nm. Series of 250 frames (128 × 64 pixels/frame) were collected at 25 ms/frame. Images were analysed using custom-made software. Fluorescence, corrected for background signal in regions outside the cells, was measured within defined regions of interest (ROIs; *F*) and normalized to resting (*F*~0~) values. Peak *F*/*F*~0~ values were calculated through each time series for each myocyte and a mean peak *F*/*F*~0~ was calculated for that series. Where indicated, cells were paced at 1 Hz (5 V above threshold of 30--60 V for 2 ms) with two field electrodes. Ca^2+^ transients were measured both from ROIs covering entire cells, as well as localized ROIs.

Myocytes loaded with Fluo-3 AM were selected for the study of spontaneous Ca^2+^ release events (sparks) on the basis of their clear striation pattern, contraction on electrical field stimulation by 5--15% of their resting length, and an absence of spontaneous contractions during a preliminary 1 min observation period. Sparks were recorded in the line scan imaging mode before and after addition of isoproterenol at resting condition along the long axis of the myocyte. Each scan consisted of 512 pixels (=40 μm) scanned at intervals of 1 ms over 5 s. Regions were selected for such imaging with the aid of series of preliminary frame scans obtained at intervals of 25 ms over 5 s from which a presence of spontaneous Ca^2+^ events could be reconstructed. The frequencies (in s^−1^) of Ca^2+^ sparks were analysed using an in-house custom-made software program. All fluorescence studies were performed at room temperature.

2.7. Statistical analysis {#s2g}
-------------------------

Data are expressed as means ± SEM. The numbers, *n*, denote either numbers of whole hearts, the number of cells, or peak *F*/*F*~0~ values. Different experimental genotype groups were compared using one-way ANOVA for correlated samples analysis of variance (SPSS software) and Student\'s unpaired *t*-test as appropriate, with *P* \< 0.05 considered statistically significant. Categorical variables were compared using *χ*^2^ and Fisher\'s exact tests, with *P* \< 0.05 considered significant. All chemical agents were purchased from Sigma-Aldrich (Poole, UK) except where otherwise indicated.

3.. Results {#s3}
===========

3.1. ECG characteristics of anaesthetized WT, *RyR2^+/S^*, and *RyR2^S/S^* mice {#s3a}
-------------------------------------------------------------------------------

Gross morphological and light microscopic (haematoxylin and eosin: [Supplementary material online, *Figure S1*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq229/DC1)*A*, *C*, and *E*; Masson trichrome: [Supplementary material online, *Figure S1*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq229/DC1)*B*, *D*, and F) examination showed no obvious structural differences and indistinguishable heart to body weight ratios between WT ([Supplementary material online, *Figure S1*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq229/DC1)*A* and *B*), *RyR2^+/S^* ([Supplementary material online, *Figure S1*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq229/DC1)*C* and *D*), and *RyR2^S/S^* ([Supplementary material online, *Figure S1*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq229/DC1)*E* and *F*) groups. *Figure [1](#CVQ229F1){ref-type="fig"}* shows typical ECG records from steadily beating anaesthetized WT (*Figure [1](#CVQ229F1){ref-type="fig"}A* and *B*), *RyR2^+/S^* (*Figure [1](#CVQ229F1){ref-type="fig"}C* and *D*), and *RyR2^S/S^* hearts (*Figure [1](#CVQ229F1){ref-type="fig"}E* and *F*) both before (*Figure [1](#CVQ229F1){ref-type="fig"}A*, *C*, and *E*) and after addition of isoproterenol (2.0 mg/kg; *Figure [1](#CVQ229F1){ref-type="fig"}B*, *D*, and *F*). *Table [1](#CVQ229TB1){ref-type="table"}* summarizes ECG parameters when hearts were in normal sinus rhythm. These were statistically indistinguishable between all three groups, under both conditions, apart from increases in heart rates (*P* \< 0.01, 0.01, and 0.05 in WT, *RyR2^+/S^*, and *RyR2^S/S^*, respectively; *n* = 8 mice in each group) produced by isoproterenol. However, there were contrasting atrial and ventricular arrhythmogenic features. None of the WT studied (*n* = 8) showed arrhythmias whether before or after addition of isoproterenol (*Figure [1](#CVQ229F1){ref-type="fig"}A* and *B*). In contrast, VT and VF did occur in the *RyR2^+/S^* and *RyR2^S/S^* confirming earlier results.^[@CVQ229C11]^ Furthermore, of the *RyR2^+/S^* (*n* = 8), one heart showed spontaneous bigeminy lasting for 13.2 s before and three showed ventricular arrhythmias after addition of isoproterenol. All three of the latter showed episodes of bigeminy lasting 0.4--5.8 s (*Figure [1](#CVQ229F1){ref-type="fig"}D*), two showed multiple episodes of bidirectional VT (BVT) lasting from 0.5 to 2.5 s. Finally, of the eight *RyR2^S/S^* mice, one showed episodes of spontaneous bigeminy (*Figure [1](#CVQ229F1){ref-type="fig"}E*) and BVT both before and after addition of isoproterenol (*Figure [1](#CVQ229F1){ref-type="fig"}F*). In addition, after addition of isoproterenol, all the *RyR2^S/S^* mice showed multiple ventricular ectopic beats. Four showed episodes of bigeminy lasting from 0.5 to 7.4 s, five showed BVT lasting for 0.5--59.4 s, two showed monomorphic VT lasting from 0.8 to 23.0 s, and one showed multiple PVT episodes lasting from 0.5 to 28.7 s. In contrast, none of the WT, *RyR2^+/S^*, or *RyR2^S/S^* showed spontaneous atrial tachycardia (AT) and AF whether in the presence or absence of isoproterenol. Table 1Comparison of *in vivo* ECG parameters in anaesthetized WT, *RyR2^+/S^*, and *RyR2^S/S^*, before and after addition of isoproterenolConditionsGenotype*n*Heart rate (b.p.m.)PR interval (ms)P-wave duration (ms)QRS duration (ms)QT interval (ms)QTc interval (ms)ControlWT8422.4 ± 17.145.2 ± 3.69.2 ± 0.812.6 ± 0.738.9 ± 4.532.3 ± 3.6*RyR2^+/S^*8391.4 ± 14.849.6 ± 3.010.3 ± 1.212.3 ± 0.938.0 ± 2.730.6 ± 2.4*RyR2^S/S^*8422.2 ± 28.543.7 ± 2.29.4 ± 0.811.1 ± 0.842.8 ± 7.134.5 ± 4.7IsoproterenolWT8503.1 ± 26.5\*\*53.4 ± 6.410.0 ± 1.014.2 ± 1.047.5 ± 4.343.3 ± 3.9*RyR2^+/S^*8464.1 ± 17\*\*57.4 ± 6.39.8 ± 1.013.4 ± 1.040.6 ± 1.835.6 ± 1.5*RyR2^S/S^*8513.0 ± 26.1\*49.8 ± 5.711.6 ± 2.211.3 ± 1.043.2 ± 5.139.1 ± 3.7[^1] Figure 1*In vivo* ECG records from anaesthetized WT, *RyR2^+/S^*, and *RyR2^S/S^*, before and after addition of isoproterenol. (*A* and *B*) WT hearts in normal sinus rhythm under both conditions. (*C*) Normal sinus rhythm before and (*D*) episodes of bigeminy following addition of isoproterenol in *RyR2^+/S^*. Episodes of (*E*) bigeminy before and (*F*) BVT after adding isoproterenol in *RyR2^S/S^*.

3.2. *In vivo* stimulation studies {#s3b}
----------------------------------

The subsequent experiments then investigated for the presence or absence of arrhythmic properties during programmed stimulation of the *in vivo* preparation. First, oesophageal pacing was applied at a 100 ms CL for 30 s. Five animals were studied in each group. None of the WT or heterozygotes showed atrial arrhythmia whether before and after addition of isoproterenol. One *RyR2^+/S^* mouse showed bigeminy both before and after addition of isoproterenol. Of the *RyR2^S/S^*, one animal showed ventricular arrhythmias before addition of isoproterenol and two showed ventricular arrhythmias after addition of isoproterenol, one of which was a BVT and the other was bigeminy. However, none of these showed atrial arrhythmias.

Secondly, burst pacing was applied to three mice from each group. Hearts initially showing intrinsic activity were paced at a CL of 40 ms in bursts of 2 s duration. This CL was then decreased in successive 2 s bursts in 2ms decrements following sets of three cycles until a CL of 20 ms was reached. Cardiac electrical activity was then measured immediately following such stimulation when hearts were then permitted to resume intrinsic activity for 5 min. Results were compared in hearts both before and after the addition of isoproterenol. None of the three WT mice studied showed either AT and AF whether or not isoproterenol was present (*Figure [2](#CVQ229F2){ref-type="fig"}A* and *B*). However, two mice showed isolated ectopic ventricular beats after burst pacing after addition of isoproterenol. In contrast, of the three *RyR2^+/S^* mice studied, one showed atrioventricular block after burst pacing both before and after addition of isoproterenol. One showed an AT episode following burst pacing lasting 1.78 s (*Figure [2](#CVQ229F2){ref-type="fig"}C*) and one animal showed spontaneous ventricular bigeminy before addition of isoproterenol. However, there were no atrial arrhythmic episodes after addition of isoproterenol (*Figure [2](#CVQ229F2){ref-type="fig"}D*). Of the three *RyR2^S/S^* mice studied, two showed spontaneous bigeminy and sustained BVT (*Figure [2](#CVQ229F2){ref-type="fig"}E*) before addition of isoproterenol. All three *RyR2^S/S^* mice showed BVT after burst pacing both before and after addition of isoproterenol (*Figure [2](#CVQ229F2){ref-type="fig"}F*); this made it difficult to clarify the atrial phenotype. Figure 2ECG records obtained during oesophageal stimulation. Typical results from (*A* and *B*) WT hearts, (*C* and *D*) *RyR2^+/S^*, and (*E* and *F*) *RyR2^S/S^* hearts before (*A*, *C*, and *E*), and following (*B*, *D*, and *F*) addition of isoproterenol. The letter 'p' indicates P-wave.

3.3. Comparison of atrial arrhythmogenicity in isolated WT, *RyR2^+/S^*, and *RyR2^S/S^* hearts {#s3c}
-----------------------------------------------------------------------------------------------

Experiments in isolated Langendorff-perfused hearts then explored for spontaneous and provoked atrial arrhythmias. A comparison of simultaneously recorded bipolar atrial and ventricular traces made it possible to attribute observed arrhythmias to either atrial or ventricular activity. Of intrinsically beating WT (*Figure [3](#CVQ229F3){ref-type="fig"}A* and *B*), *RyR2^+/S^* (*Figure [3](#CVQ229F3){ref-type="fig"}C* and *D*), and *RyR2^S/S^* (*Figure [3](#CVQ229F3){ref-type="fig"}E* and *F*), before (*Figure [3](#CVQ229F3){ref-type="fig"}A*, *C*, and *E*) and after introduction of isoproterenol (100 nM; *Figure [3](#CVQ229F3){ref-type="fig"}B*, *D*, and *F*), atrial arrhythmias occurred in isoproterenol-treated WT and *RyR2^+/S^* (*Figure [3](#CVQ229F3){ref-type="fig"}A*--*D*) and in *RyR2^S/S^* both before and after isoproterenol administration (*Figure [3](#CVQ229F3){ref-type="fig"}E* and *F*). Similar recordings were made during PES in WT (*Figure [4](#CVQ229F4){ref-type="fig"}A* and *B*), *RyR2^+/S^* (*Figure [4](#CVQ229F4){ref-type="fig"}C* and *D*) and *RyR2^S/S^* (*Figure [4](#CVQ229F4){ref-type="fig"}E* and *F*) before (*Figure [4](#CVQ229F4){ref-type="fig"}A*, *C*, and *E*) and after (*Figure [4](#CVQ229F4){ref-type="fig"}B*, *D*, and *F*) isoproterenol treatment. *Figure [4](#CVQ229F4){ref-type="fig"}* exemplifies non-sustained (*Figure [4](#CVQ229F4){ref-type="fig"}C*) and sustained (*Figure [4](#CVQ229F4){ref-type="fig"}D*) atrial arrhythmias from *RyR2^+/S^* and sustained arrhythmias in *RyR2^S/S^* (*Figure [4](#CVQ229F4){ref-type="fig"}E* and *F*) hearts. MAP recordings differentiated these phenomena into AT, as exemplified in an *RyR2^+/S^* heart (*Figure [5](#CVQ229F5){ref-type="fig"}A* and *B*) or AF, as exemplified in an *RyR2^S/S^* heart (*Figure [5](#CVQ229F5){ref-type="fig"}C* and *D*) both before (*Figure [5](#CVQ229F5){ref-type="fig"}A* and *C*) and after (*Figure [5](#CVQ229F5){ref-type="fig"}B* and *D*) addition of isoproterenol. Figure 3BEG records from both the atria and ventricles of WT, *RyR2^+/S^*, and *RyR2^S/S^* hearts before and after introduction of isoproterenol. Atrial (a) and ventricular (b) BEG records showing normal sinus rhythm before (*A* and *C*), but episodes of AT after addition of isoproterenol (*B* and *D*) in intrinsically beating WT (*A* and *B*) and *RyR2^+/S^* (*C* and *D*). Episodes of AT in intrinsically beating *RyR2^S/S^* (*E* and *F*) both before (*E*) and following addition of isoproterenol (*F*). In panel (*A*), contributions from atrial activation are labelled 'A' and those from ventricular activation are labelled 'V'. Figure 4BEG records obtained from atria and ventricles during programmed electrical stimulation in WT, *RyR2*^+/S^ and *RyR2*^S/S^ before and after introduction of isoproterenol. Atrial (a) and ventricular (b) BEG records showing normal (*A*) non-sustained (*B* and *C*) and sustained (*D*) AT before (*A* and *C*) and after (*B* and *D*) introduction of isoproterenol in WT and *RyR2*^+/S^. Episodes of sustained AT occurred in both conditions in *RyR2*^S/S^ (*E* and *F*). The short vertical bars below the traces give the timings of the S1, and the long bars the S2 stimuli in the PES sequences. Figure 5MAP recordings from *RyR2^+/S^* and *RyR2^S/S^* during PES before and after introduction of isoproterenol. (*A*) Non-sustained and (*B*) sustained tachycardia observed before (*A*) and after (*B*) introduction of isoproterenol in *RyR2^+/S^*. Episodes of sustained AT were observed both before (*C*) and after (*D*) introduction of isoproterenol arrhythmias in *RyR2^S/S^* following PES. (*E* and *F*) Numbers of episodes sorted by durations of \<1.0, 1.0--5.0, and \>5.0 s before (*E*) and following (*F*) addition of isoproterenol. There were larger numbers of arrhythmic episodes of longer duration in the *RyR2^S/S^* before addition of isoproterenol (*E*) than the remaining groups. An increased incidence particularly of brief arrhythmic episodes (\<1.0 s) occurred in all experimental groups (*F*) following addition of isoproterenol.

*Table [2](#CVQ229TB2){ref-type="table"}* summarizes the incidence of hearts showing atrial arrhythmogenesis (Columns 3 and 7) for which different experimental groups were tested against each other for significance. The remaining columns provide details concerning the number of episodes observed as well as their durations. This demonstrates that under conditions of intrinsic pacing, there were no significant differences in the incidence of atrial arrhythmic episodes between groups. However, during both regular pacing and PES, the *RyR2^S/S^*, but not the *RyR2^+/S^*, was more arrhythmogenic than WT in the absence of isoproterenol. In contrast, both the *RyR2^+/S^* and the *RyR2^S/S^* were more arrhythmogenic than untreated WT in the presence of isoproterenol. Table 2Summary of atrial arrhythmogenic properties in WT, *RyR2^+/S^*, and *RyR2^S/S^* before and after addition of isoproterenolPacing protocolGenotypeIncidence of hearts showing AT and AF before addition of isoproterenolIncidence of hearts showing AT and AF after addition of isoproterenolArrhythmic incidence in *n* heartsNo. of episodesDuration of episodes (range) (s)Duration of episodes (mean ± SEM)Arrhythmic incidence in *n* heartsNo. of episodesDuration of episodes (range) (s)Duration of episodes (mean ± SEM)IntrinsicWT0/140001/14100.15--8.241.20 ± 2.51*RyR2^+/S^*0/160002/1560.13--5.041.28 ± 1.87*RyR2^S/S^*3/18280.17--5.990.89 ± 1.233/17360.28--8.012.77 ± 2.29RegularWT0/140002/14170.26--26.532.51 ± 6.22*RyR2^+/S^*1/1610.210.21 ± 0.005/15210.14--3.330.31 ± 0.69*RyR2^S/S^*5/18\*300.22--8.542.3 ± 3.154/17100.1--7.382.84 ± 3.57PESWT3/14270.09--2.720.31 ± 0.056/12290.1--0.720.28 ± 0.18*RyR2^+/S^*6/14200.15--3.730.99 ± 1.035/14^¶^100.1--4.861.68 ± 1.89*RyR2^S/S^*12/16\*\*360.1--5.590.59 ± 1.259/12^¶^290.13--6.030.83 ± 1.27[^2]

*Figure [5](#CVQ229F5){ref-type="fig"}E* and *F* classifies the numbers of such episodes into durations of \<1.0, 1.0--5.0, and \>5.0 s. Results compared before (*Figure [5](#CVQ229F5){ref-type="fig"}E*) and after (*Figure [5](#CVQ229F5){ref-type="fig"}F*) addition of isoproterenol demonstrate larger numbers of arrhythmic episodes of greater duration in the *RyR2^S/S^* than the remaining groups. Isoproterenol increased the incidence of arrhythmic episodes, particularly of brief episodes (\<1.0 s) in all the experimental groups.

3.4. Atrial arrhythmogenesis in isolated *RyR2^+/S^* and *RyR2^S/S^* hearts takes place in the absence of alterations in action potential waveforms and refractory periods {#s3d}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Previous studies have implicated shortenings of the APD~90~, and of the atrial effective refractory periods (AERPs) in re-entrant atrial arrhythmogenicity in murine hearts.^[@CVQ229C21]^ The AERP in particular appeared important as the determinant of the time period in which a given myocardial region is capable of re-excitation in response to a stimulus, whether appropriate and originating from the sinus node, or abnormal ectopic or re-entrant activity.^[@CVQ229C22]^ In contrast, prolongations in these parameters conferred protection from such arrhythmic effects in studies of murine hearts modelling genetic modifications in the Na^+^ channel.^[@CVQ229C23]^ In contrast, the atrial arrhythmogenicity associated with *RyR2* modification observed here were not accompanied by alterations in either of these parameters, and therefore appear to reflect a contrasting mechanism. *Table [3](#CVQ229TB3){ref-type="table"}* (Columns 2 and 3) thus demonstrates statistically indistinguishable APD~90~ values obtained from hearts in each of the three groups during regular pacing; *Table [3](#CVQ229TB3){ref-type="table"}* (Columns 4 and 5) demonstrates statistically identical AERPs, given by the shortest S1S2 interval that failed to elicit an action potential. None of these parameters were significantly altered by the introduction of isoproterenol. Table 3Action potential parameters obtained in WT, *RyR2^+/S^* and *RyR2^S/S^* before and after introduction of isoproterenolGenotypeAPD~90~ (ms)AERP (ms)Control (mean ± SEM) (*n*)Isoproterenol (mean ± SEM) (*n*)Control (mean ± SEM) (*n*)Isoproterenol (mean ± SEM) (*n*)WT20.26 ± 1.57 (6)17.14 ± 0.84 (5)24.62 ± 1.30 (13)23.31 ± 1.48 (13)*RyR2^+/S^*18.61 ± 1.33 (9)19.86 ± 0.54 (5)23.64 ± 1.64 (14)25.18 ± 2.71 (17)*RyR2^S/S^*19.02 ± 1.06 (7)19.87 ± 1.12 (6)26.05 ± 1.95 (20)25.95 ± 0.95 (19)

3.5. Atrial arrhythmogenesis in isolated *RyR2^+/S^* and *RyR2^S/S^* hearts is associated with abnormal Ca^2+^ homeostasis {#s3e}
--------------------------------------------------------------------------------------------------------------------------

In contrast, confocal fluorescence microscope studies in fluo-3-loaded atrial myocytes demonstrated contrasting patterns in Ca^2+^ homeostasis between the three groups. *Figure [6](#CVQ229F6){ref-type="fig"}* shows typical fluorescence traces obtained from WT (*Figure [6](#CVQ229F6){ref-type="fig"}A* and *B*), *RyR2^+/S^* (*Figure [6](#CVQ229F6){ref-type="fig"}C* and *D*), and *RyR2^S/S^* (*Figure [6](#CVQ229F6){ref-type="fig"}E* and *F*) myocytes regularly field-stimulated at 1.0 Hz before (*Figure [6](#CVQ229F6){ref-type="fig"}A*, *C*, and *E*) and after introduction of isoproterenol (100 nM; *Figure [6](#CVQ229F6){ref-type="fig"}B*, *D*, and *F*). In contrast to WT and *RyR2^+/S^*, *RyR2^S/S^* myocytes showed a significantly greater incidence of evoked Ca^2+^ responses that showed episodes of diastolic Ca^2+^ release in the absence of isoproterenol. The introduction of isoproterenol resulted in an increase in such incidences in all the groups, despite an absence of significant difference in peak *F*/*F*~0~ values evoked by the regular stimulation (*Table [4](#CVQ229TB4){ref-type="table"}*). All these findings are in exact parallel with the incidence of atrial arrhythmia displayed in *Table [2](#CVQ229TB2){ref-type="table"}*. Such diastolic phenomena would be expected to result in a formation of delayed after-depolarization events resulting from increased electrogenic Na^+^--Ca^2+^ exchanger following the consequent elevations in cytoplasmic Ca^2+^. These could potentially alter membrane voltage to threshold to give rise to extrasystolic triggered activity. Table 4Results of confocal fluorescence microscopy of fluo-3-loaded atrial myocytes during regular stimulationGenotypeControlIsoproterenolNumber of cells (*n*)Number of peaksPeak fluorescence expressed as *F*/*F*~0~Number of episodes of diastolic releaseNumber of cells (*n*)Number of peaksPeak fluorescence expressed as *F*/*F*~0~Number of episodes of diastolic releaseWT91413.06 ± 0.17117843.18 ± 0.4213\*\*\**RyR2^+/S^*151793.64 ± 0.2512111322.91 ± 0.2782^\#\#\#,^\*\*\*\**RyR2^S/S^*101152.81 ± 0.2839^\#\#\#,¶¶¶^141682.94 ± 0.23224^\#\#\#,¶¶¶,^\*\*\*[^3] Figure 6Ca^2+^ transients from regularly stimulated fluo-3-loaded WT, *RyR2^+/S^*, and *RyR2^S/S^* atrial myocytes studied using confocal microscopy before and after addition of isoproterenol. Left (*A*, *C*, and *E*) and right (*B*, *D*, and *F*) columns illustrate WT (*A*, *B*), *RyR2^+/S^* (*C* and *D*), and *RyR2^S/S^* (*E* and *F*) Ca^2+^ transients before (*A*, *C*, and *E*) and following addition of isoproterenol (*B*, *D*, and *F*). Regular Ca^2+^ transients without (*A*) and showing diastolic Ca^2+^ release (*B*) before (*A*) and following (*B*) addition of isoproterenol in WT (*A* and *B*). Diastolic Ca^2+^ release (*C*) whose incidence was increased by isoproterenol (*D*) in RyR2^+/S^. Multiple episodes of diastolic Ca^2+^ release (*E*) accentuated by addition of isoproterenol (*F*) in *RyR2^S/S^*. Markers below the traces indicating timing of the regular stimulation. (*G* and *H*) Frequencies of Ca^2+^ sparks among the three genotypes; \*\*denote differences to a significance level of *P* \< 0.01 (*G*), and before and after addition of isoproterenol; ¶¶ and \#\# both denote differences to a significance level of *P* \< 0.01 (*H*).

The above findings correlated with our estimates of spontaneous Ca^2+^ release events obtained in quiescent atrial myocytes. The presence of these was clearly demonstrable in the preliminary frame scan images obtained from cells from all three experimental groups both before and after addition of isoproterenol. Furthermore, analysis of their frequencies correlated closely with the corresponding arrhythmic tendencies that were observed at the level of whole hearts. Thus, *Figure [5](#CVQ229F5){ref-type="fig"}G* and *H*, [Supplementary material online, *Figure S2*,](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq229/DC1) and *Table [5](#CVQ229TB5){ref-type="table"}* demonstrate significantly higher event frequencies in *RyR2^S/S^* (*P* \< 0.01) but not *RyR2^+/S^* compared with WT and in *RyR2^S/S^* compared with *RyR2^+/S^* in the absence of isoproterenol. These differences disappeared following addition of isoproterenol, an effect attributable to its action in significantly (*P* \< 0.01) increasing event frequency in WT and *RyR2^+/S^* but not *RyR2^S/S^*. Table 5Frequencies of spontaneous Ca^2+^ release events in WT, *RyR2^+/S^*, and *RyR2^S/S^* atrial myocytes before and after addition of isoproterenolWT (*n*)*RyR2^+/S^* (*n*)*RyR2^S/S^* (*n*)Before isoproterenol0.35 ± 0.12 (12)0.17 ± 0.07 (9)1.78 ± 0.44^¶¶,\#\#^ (10)After isoproterenol2.00 ± 0.47 (14)\*\*2.89 ± 0.43\*\* (11)1.20 ± 0.40 (10)[^4][^5][^6]

4.. Discussion {#s4}
==============

The present experiments explored for and characterized acute atrial arrhythmogenic properties in recently developed hetero-(*RyR2^+/S^*) and homozygotic (*RyR2^S/S^*) *RyR2-P2328S* murine models for CPVT, and investigated their physiological background. The *RyR2-P2328S* mutation was first described in a Finnish family with CPVT.^[@CVQ229C3],[@CVQ229C24]^ However, clinical reports also associate occasional acute atrial arrhythmias in patients carrying *RyR2* mutations.^[@CVQ229C12],[@CVQ229C25]^ Thus, in reports including a family with *RyR2-P2328S*, although all carriers exhibited polymorphic VT and/or VF, three patients also showed non-sustained AT.^[@CVQ229C24]^ The present experiments demonstrated acute arrhythmogenic properties in structurally normal atria of *RyR2-P2328S* hearts. They correlated these with altered Ca^2+^ homeostasis in an absence of abnormalities in action potential repolarization for the first time.

First, in intact anaesthetized animals, mutations in *RyR2-P2328S* did not alter baseline ECG parameters during normal sinus rhythm. ECG parameters in WT, *RyR2^+/S^*, and *RyR2^S/S^* hearts were statistically indistinguishable. None of three groups showed significant differences in RR, P-wave, QRS complex, and QTc intervals whether before and after addition of isoproterenol apart from increased heart rates. These findings paralleled previous clinical reports of the family of *RyR2-P2328S* mutation carriers^[@CVQ229C24]^ and other clinical examples.^[@CVQ229C15]^ The latter thus also showed normal RR intervals, atrioventricular conduction, QRS complex morphology, ST-segment, and T-wave pattern, although QTc intervals of affected individuals were slightly longer than those of controls.^[@CVQ229C24]^ The present findings in *RyR2-P2328S* hearts also agreed with baseline ECG parameters in the alternative *RyR2*-*R4496C* and *RyR2-R176Q* mouse models.^[@CVQ229C10],[@CVQ229C26]^

*RyR2^+/S^* and *RyR2^S/S^* but not WT hearts showed episodic spontaneous ventricular arrhythmogenesis in both the absence and the presence of isoproterenol. Such ventricular arrhythmias often took the form of BVTs in common with clinical findings, which also describe exercise-induced supraventricular arrhythmias that precede, but which are less common than ventricular tachyarrhythmias in CPVT,^[@CVQ229C1],[@CVQ229C27],[@CVQ229C28]^ making it less likely they are their direct cause. The present results similarly showed no incidents of spontaneous supraventricular arrhythmogenesis. The observed disruptions with the mutant *RyR2* described below therefore likely reflect acute atrial arrhythmogenesis rather than representing chronic arrhythmogenic changes following electrical remodeling.^[@CVQ229C29]^

Secondly, isolated *RyR2^S/S^* hearts showed atrial arrhythmogenicity in the absence of alterations in action potential waveforms and AERPs. Thus, BEG and MAP recordings in isolated perfused preparations demonstrated significantly higher arrhythmogenic incidences in *RyR2^S/S^*, but not *RyR2^+/S^*, relative to WT hearts during both regular pacing and PES, even before addition of isoproterenol. The addition of isoproterenol increased such incidences in all three groups. These findings were in contrast to the ECG findings in the intact mice. There are thus detailed differences between the murine and the previously described clinical findings, with the murine homozygote, but not heterozygote, showing an atrial arrhythmic phenotype, but then, in the absence of catecholaminergic challenge.

Thirdly, APD~90~ and AERPs were indistinguishable between the three groups. This contrasts with predictions of a re-entrant arrhythmogenic substrate resulting from abnormalities in action potential recovery as has been associated with gain-of-function *KCNQ1* mutations. The latter involves the Kv7.1 α-subunit responsible for the slow delayed rectifier K^+^. It results in a shortened APD~90~ and AERP.^[@CVQ229C30]^

Finally, studies in regularly stimulated isolated fluo-3-loaded *RyR2^S/S^*, but not *RyR2^+/S^* or WT, atrial myocytes contrastingly showed episodes of diastolic Ca^2+^ release under confocal microscopy. *RyR2* mutation thus alters atrial Ca^2+^ homeostasis. The introduction of isoproterenol then resulted in significant diastolic Ca^2+^ release in all three groups. These findings directly parallel the corresponding observations of the presence or absence of increased atrial arrhythmogenesis in the isolated perfused hearts described above. These findings thus implicate alterations in Ca^2+^ homeostasis in the observed atrial arrhythmic properties. This could then take place through ectopic firing that might contribute to triggering of arrhythmia.^[@CVQ229C31]^ These findings additionally directly parallel our earlier reports which correlated acute atrial arrhythmogenesis in intact WT hearts with effects of altered Ca^2+^ homeostasis in atrial myocytes following pharmacological manipulation.^[@CVQ229C20]^
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[^1]: Control vs. isoproterenol addition \**P* \< 0.05, \*\**P* \< 0.01.

[^2]: Note: vs. WT \**P* \< 0.05, \*\**P* \< 0.01; vs. WT before addition of isoproterenol ^¶^*P* \< 0.05.

[^3]: Note: vs. control \*\*\**P* \< 0.001; vs. WT ^\#\#\#^*P* \< 0.001; vs. *RyR2^+/S^* ^¶¶¶^*P* \< 0.001.

[^4]: \*\**P* \< 0.01 when compared with the corresponding findings obtained before addition of isoproterenol.

[^5]: ^¶¶^*P* \< 0.01 when compared with findings obtained from WT before addition of isoproterenol.

[^6]: ^\#\#^*P* \< 0.01 when compared with findings obtained from *RyR2^+/S^* before addition of isoproterenol.
